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Abstract 
Melanoma is the most aggressive form of skin cancer and is notoriously resistant 
to all current modalities of cancer therapy. Therefore，the development of novel, 
melanoma-specific agents is highly warranted. Recent studies showed that betulinic 
acid, a triterpenoid derived from white birch tree, exhibits strong melanoma-specific 
activities. 
Here, we report the first evidence that a lupane-type triterpenoid 
3a-hydroxy-lup-20(29)-ene-23,28-dioic acid (HLDA), purified from the ivy tree 
Schefflera heptaphylla (L.) Frodin, inhibited the growth of cancer cells originated 
from different histotypes in vitro after 72 h of treatment. The values of IC50 were 23 
|j,g/ml (melanoma A375), 33 jag/ml (hepatocellular carcinoma HepG2), 40 |ig/ml 
(breast carcinoma MCF-7), 86 )j.g/ml (prostate carcinoma PC-3)，and 90 |ig/ml 
(laryngeal carcinoma HEp2). In addition, the HLDA-rich ethyl acetate fraction from S. 
heptaphylla also inhibited the growth of cancer cells, with the IC50 values of 46, 52, 
76，100 and 110 }ig/ml, respectively. The most responsive cancer cell line, human 
melanoma A3 75, was thus chosen for further analysis on the anticancer properties of 
HLDA and the ethyl acetate fraction. 
Both HLDA and the ethyl acetate fraction at their IC50 induced apoptosis in the 
A375 cells as evidenced by the presence of sub-Gi cells in DNA flow cytometry and 
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PARP cleavage in Western blot analysis. However, HLDA did not affect the cell cycle 
progression of the melanoma cells while the ethyl acetate fraction arrested the cells in 
the S and G2/M phase. 
HLDA and the ethyl acetate fraction were found to deplete the antiapoptotic 
Bcl-2 family protein expression (HLDA depleted BC1-XL while ethyl acetate fraction 
depleted BC1-XL and Bcl-2) and induce caspase-8 and caspase-9 cleavage in the 
melanoma cells. Furthermore, the HLDA-induced apoptosis was completely inhibited 
by pretreatmeiit with general caspase inhibitor (Z-VAD-FMK) and partially blocked 
by caspase-8 inhibitor (Ac-IETD-CHO) or caspase-9 inhibitor (Z-LEHD-FMK). On 
the other hand, the ethyl acetate fraction-induced apoptosis was partially blocked by 
general caspase inhibitor, caspase-8 inhibitor or caspase-9 inhibitor. All these results 
suggest that both HLDA and the ethyl acetate fraction inhibit the growth of melanoma 
A375 at least by triggering the mitochondria-dependent apoptosis. Moreover, 
HLDA-induced apoptosis was mainly executed through caspase-dependent pathway 
while the ethyl acetate fraction-induced apoptosis involved both caspase-dependent 
and caspase-independent pathways. 
The ethyl acetate fraction exhibited anticancer effects in vivo in the 
DMBA/TPA-induced carcinogenesis model and athymic nude mice model. Both 
models, the mice were topically treated with the ethyl acetate fraction at doses up to 
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40 mg/ml. In the skin carcinogenesis model, the papilloma incidence was significantly 
reduced after treatment twice a week for 20 consecutive weeks, with 100% inhibition 
of papilloma incidence at the dose of 40 mg/ml. Furthermore, in the athymic BALB/c 
nude mice model, the tumor size of transplanted melanoma A375 regressed after 
treatment for 10 days, with 73% tumor growth inhibition at the dose of 2 mg/ml when 
compared with control mice. 
In conclusion, the anticancer activities of HLDA and the ethyl acetate fraction 
from S. heptaphylla on the human melanoma A375 cells are both mediated by 
apoptosis induction, at least partially, through regulation of Bcl-2 family protein 
expression and activation of caspases. A further in-depth study to define active agents 
in the ethyl acetate fraction capable of affording the observed antitumor-promoting 














度(ICsG)分別爲23，33, 40，86和90昭/ml °此外’我們同時亦對萃取HLDA的 
乙酸乙酯分層萃取物加以硏究，於同樣的實驗設定下，此分層萃取物的ICsG分別 
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Chapter 1 
Introduction 
1.1 General Introduction 
Traditional Chinese Medicine (TCM) is a comprehensive system of medical 
thought, pathophysiological concepts, and therapeutic interventions that developed 
more than 4,000 years. It is practised by about one-fifth of the world's population and 
is becoming increasingly popular in many medical contexts, particularly among 
patients with cancer (Cao et al., 2003; Niu and Liu, 2003). TCM encompasses a range 
of modalities including herbal medicine, acupuncture, medical qigong, dietary 
recommendations, and meditation. Backed by centuries of experience, China's huge 
pharmacopoeia contains thousands of plant, animal, or mineral origins, and most of 
which are herbs. Among the components of TCM, herbal or botanical agents possess 
complex biological activities that could affect many aspects of carcinogenesis (Tang 
et al., 2003). At least half of Chinese folk remedies have some kinds of scientific basis 
for their reputed claims, according to a study by National Academy of Sciences on 
796 Chinese herbal remedies (Walters, 1993). The Institute for Traditional Medicine 
(ITM) made an effort to alert practitioners of Chinese medicine in the U.S. to the 
promising role for Chinese herbs, with updated information provided over the years. 
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In recent years there has been a trend to integrate TCM with standard Western 
medicine in attempts to optimize the treatment outcomes, minimize the side effects of 
surgery, radiotherapy and chemotherapy, increase the immune function, and to 
improve survival. 
Schefflera heptaphylla is a well-known native species in Hong Kong. It is widely 
used in combination with other herbs for the treatment of common cold in Hong Kong. 
Moreover, the wood of this plant has been used to treat cancer in Taiwan (Kan, 1975). 
A variety of compounds have been isolated from S. heptaphylla. These include 
steroids, sesquiterpenes, diterpenes, triterpenes, and sugars (Kitajima and Tanaka, 
1989; Sung et al., 1992). Recently, we have identified a lupane-type triterpene 
3a-hydroxylup-20(29)-ene-23,28-dioic acid (HLDA) from the leaves of S. 
heptaphylla (Li, 2004). It has a highly similar chemical structure with betulinic acid, a 
reported triterpene with anticancer activity, particularly on melanoma (Pisha et al., 
1995; Zanon et al” 2004). This prompted us to evaluate the antiproliferative activity 
of HLDA on different cancer cell lines. Since HLDA was derived from the ethyl 
acetate fraction of S. heptaphylla, the antiproliferative activity of this fraction was 
also studied. 
Kerr et al. (1972) originally described two forms of cell death which may occur 
in the absence of pathological manifestations, necrosis and apoptosis. Necrosis is 
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characterized by high amplitude swelling of the mitochondria, nuclear flocculation, 
and uncontrolled cell lysis (Cotter et al., 1990). On the other hand, apoptosis is a 
programmed cell death controlled by a large number of signaling molecules (Walker 
et al., 1988). Because deregulated proliferation and inhibition of apoptosis lie at the 
heart of all tumour development, they present two obvious targets for therapeutic 
intervention in all cancers (Evan and Vousden, 2001). Chemotherapeutic drugs which 
cause DNA damage generally kill tumor cells by inducing apoptosis (Cotter et al., 
1990; Gatti and Zunino, 2005). Therefore, a better understanding on apoptosis 
induction and exploitation of apoptosis-based therapies for cancer treatment are 
crucial (Ghobrial et al, 2005). Due to the improvement of understanding of apoptosis 
mechanisms, novel strategies have emerged for restoring sensitivity of apoptosis in 
cancer, and clinical testing of several of these approaches is underway (Reed, 2003). 
Tissue culture-based in vitro studies help to elucidate many of the autonomous 
changes that result in cancer and help to find out at least some of the possible 
anticancer mechanisms of potent compounds. However, it is not possible to accurately 
model the complex process of tumor formation, invasion, and metastasis entirely in 
vitro. Therefore, after promising anticancer agents have been selected from the in 
vitro studies, information like toxicity and dose-response relationship are usually 
studied in animal models (Zee-Cheng and Cheng, 1988; Frijhoff et al” 2004). Mouse 
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has been developed as a tumor-bearing animal in the last 40 years and remains the 
animal of choice for cancer models. Mouse models of cancer are often good 
approximations of human cancer counterparts as they recapitulate the multistep nature 
of tumor progression (Van Dyke and Jacks, 2002). The possible drug-related toxicity 
can also be studied in the mouse models (Voskoglou-Nomikos et aL, 2003). As the 
extraction yield of the ethyl acetate fraction from S. heptaphylla is significantly higher 
than that of HLDA, it was chosen for further anticancer studies in vivo. 
Cancer preventive effect of the fraction was studied using the chemically induced 
skin carcinogenesis model. Cancer therapeutic effect of the fraction，on the other hand, 
was evaluated with the A375 xenograft in athymic nude mice. 
4 
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1.2 Literature Review 
1.2.1 Cancer and melanoma 
Cancer is a growing health problem around the world. According to a recent 
report by the World Health Oraganization, there are more than 10 millions cases of 
cancer per year worldwide. Melanoma is the leading cause of skin cancer deaths. It 
results in an estimated 7400 of the 9600 skin cancer deaths per year. (Bosenberg, 
2004). Furthermore, treatment of melanoma is relatively difficult because melanoma 
is notoriously resistant to conventional chemotherapy. The average survival period of 
patients with treatment failure is only six to ten months (Soengas and Lowe, 2003). 
Melanocytes predominantly locate at the junction of epidermis and dermis, but 
some are found in hair follicles. Melanocytes produce melanin, a pigment responsible 
for pigmentation of skin, which is important for protecting the deeper layers of the 
skin from the harmful ultraviolet radiations. However, melanocytes may sporadically 
or inherited to mutate and become malignant tumor called melanoma (Haass et al, 
2005). The causes of melanoma are related to prolonged exposure to ultraviolet 
radiation, skin color, and family history of melanoma. 
Like other types of cancers, melanoma is caused by abnormal and uncontrolled 
cell division. Development of cancer is divided into three phases: initiation, 
promotion, and progression. The initiation phase is a rapid and irreversible process 
5 
Chapter 1 Introduction 
that occurs when a normal cell is exposed to a carcinogen causing unrepairable or 
misrepaired DNA damage. The promotion phase, on the other hand, is a protracted 
process that may require several years to be completed. It consists of the expansion of 
mutated cells to form an actively proliferating, multicellular premalignant lesion. In 
the progression phase，another irreversible process occurs over a relatively short 
period, by which clones with increased proliferative capacity, invasiveness, and 
metastatic potential are produced (Sun et al, 2004). In this stage, the melanoma 
metastasizes through the blood stream or lymphatic system to other parts of the body. 
1.2.2 Anticancer drugs from natural products 
Nature has provided many effective anticancer agents in current use. There are at 
least 250,000 species of plants, of which more than one thousand plants have been 
found to possess significant anticancer properties. Various active compounds derived 
from medicinal plants have been assessed for their efficacy and tolerability in the 
treatment of cancers. These include paclitaxel and docetaxel from Taxus brevifolia; 
etoposide from Podophyllum peltatum; camptothecin from Camptotheca acuminate; 
and vinblastine and vincristine from Vinca rosea. They have well recognized 
anticancer activity in clinics (Mantle et al., 2000). The search for novel anticancer 
agents from natural sources continues through collaboration among scientists 
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worldwide (Cragg and Newman, 1999). 
Vinblastine and vincristine are two of the alkaloids from Vinca. They are used 
extensively in the treatment of childhood acute lymphoblastic leukemia (Kavallaris et 
al., 2001), Hodgkin's disease (Rueda Dominguez et al., 2004), testicular cancer 
(Einhorn, 2002), and breast cancer (Crown, 1998). The clinical interest of Vinca 
alkaloids was clearly identified as early as 1965 and so, this class of compounds has 
been used as anticancer agents for more than 30 years. They prevent mitosis in 
metaphase by binding to the beta-tubulin subunit of the alpha/beta-tubulin 
heterodimer and inhibit polymerization of microtubules (Duflos et al., 2002; Hayot et 
al., 2002). Unfortunately, despite their usefulness, drug resistance remains a serious 
clinical problem. 
Caniptothecin is a monoterpenoid indole alkaloid originally isolated from 
Camptotheca acuminata Decne，a native tree in south China, that has gained great 
attention for its significant antitumor activities in preclinical studies. Camptothecin 
and its derivatives are naturally-occurring DNA topoisomerase I inhibitors. 
Topoisomerase is an important enzyme in DNA replication, which is responsible for 
the unwinding of the supercoiled DNA. Inhibiting the activity of this enzyme will 
ultimately lead to cell death. Camptothecin and its derivatives exhibited remarkable 
anticancer activities and are in clinical trial in treating colon, breast and small cell 
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lung cancer. Irinotecan (Abigeres et aL, 1995; Bleiberg, 1999) and topotecan 
(Romanelli et aL, 1998; Clements et aL, 1999), two water-soluble derivatives of 
camptothecin, have been approved by the Food and Drug Administration (FDA) of 
the United States of America for treating colorectal and ovarian cancer. 
T a x o l ™ (Paclitaxel) is a taxane alkaloid which has been developed as an 
anticancer drug in the past three decades. In 1971，taxol was isolated and identified 
from the stem bark of the western yew, Taxus brevifolia, which is found in the 
northwest Pacific coastal region of the United States (Wani et aL, 1971). In 1992, 
taxol was approved for treatment of refractory ovarian cancer and today is used 
against breast and non-small cell lung cancers and Kaposi's sarcoma (Oberlies and 
Kroll, 2004). It was approved by the FDA for first-line therapy for the treatment of 
advanced carcinoma of the ovary in combination with cisplatin in 1998. It binds to the 
N-terminal region of beta-tubulin and promotes the formation of highly stable 
microtubules that resist depolymerization, thus preventing cell division and arresting 
the cell cycle at the G2/M phase (Schiff and Horwitz, 1980; Wang et aL, 2000). 
Unfortunately, taxol is subjected to the problem of multidrug resistance of metastatic 
melanoma. In early trials with treatment naive previously untreated metastatic 
melanoma patients, it produced a reported response rate of 16% when it was given as 
a 24 h infusion (Nathan et aL, 2000). 
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1.2.3 Challenges in treatment of melanoma 
Treatment options of melanoma are limited because of the poor response of 
melanoma to current therapies. Treatment with the alkylating agent dacarbazine 
(DTIC), the only single-agent approved by the FDA for treating metastatic melanoma, 
allows a complete response rate of only 16% (Serrone et aL, 2000). Other 
chemotherapeutic agents including vincristine, vinblastine, cisplatin, paclitaxel, 
docetaxel, and the DTIC analogue temozolomide were also failed in large randomized 
studies (Soengas and Lowe, 2003). Based on their single-agent activities, several 
combination chemotherapies have been investigated with preliminary results appeared 
promising. However, in randomized phase III trials the two most active chemotherapy 
combination regimens, cisplatin combined with vinblastine, and DTIC combined with 
the Dartmouth regimen (DTIC, cisplatin, bischloroethylnitrosourea, and tamoxifen), 
did not prove to be superior to single-agent DTIC for overall survival (Atallah and 
Flaherty, 2005). 
Melanoma-derived cell lines are often markedly chemoresistant, suggesting that 
some cellular mechanisms could mediate the generation of multidrug resistance 
(MDR) phenotype. This phenotype is often due to the expression of P-glycoprotein 
and the MDR-related proteins (Schadeiidorf et aL, 1995), which are drug transporters 
associated with the resistance to a broad spectrum of lipophilic drugs (Ichihashi and 
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Kitajima, 2001). MDR can be resulted from several distinct mechanisms, including 
alterations of tumor cell cycle checkpoints, impairment of tumor apoptotic pathways, 
repair of damaged cellular targets, and reduced drug accumulation in tumor cells. 
(Gottesman et al., 2002). Taxol and vindesine are common anticancer drugs being 
used, but both drugs are subjected to the problem of MDR in melanoma (Grottke et 
al., 2000; Nathan et al., 2000). It is noteworthy that MDR is a common phenomenon 
in malignant melanoma and therefore provides motivation for scientists to explore 
alternative approaches and to search for new anticancer agents for treatment of 
melanoma. 
1.2.4 TCM 一 New source of natural products for cancer therapy 
Traditional Chinese medicine (TCM) is a hot issue in cancer therapy nowadays. 
It is an alternative method of cancer therapy, which can be administered in oral, 
topical, or injectable forms. Among the components of TCM, herbal or botanical 
agents possess complex biological activities that could affect many aspects of 
carcinogenesis such as cell growth and proliferation, apoptosis, host-tumor 
interactions, immune function, and differentiation (Koo and Desai, 2003). 
For more than 30 years, Chinese herbs and materials derived from the herbs have 
been used as adjunct therapies for cancer patients. The application of TCM was first 
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developed clinically in China and Japan during the 1970s and was relayed to the rest 
of the world in 1983 through an international conference in Beijing which was 
followed up by press reports in English and other languages. Many anticancer drugs 
originated from plants in China have been investigated. The continuous search for 
new anticancer drugs from plants will be a fruitful frontier in cancer treatment and 
chemoprevention. 
The basic concepts of drug therapy in traditional Chinese medicine and modern 
Western medicine are very different (Cheng, 2000). In China, many drugs isolated 
from plants have been used as herbal medication before the active principles were 
identified. Some theories such as the yin-yang theory and the five-element theory 
were commonly employed to explain the rationale of using TCM. Drug therapy has 
been one of the means used in Chinese medicine to keep these elements and the flow 
of energy in balance (Borchardt，2003). However, for the modernization of TCM, 
active components in TCM for treating the disease and the underlying mechanisms 
have to be identified, as in the modern Western medicine. 
1.2.6 The genus Schefflera 
The whole Schefflera genus comprises of approximately 200 species which 
distribute in the tropical and subtropical areas of the world. Thirty seven species of 
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them are found in the southern China (Chen et al, 2002). In the "Zhong Hua Ben 
Cao", some of them are recorded as medical plants, including S. arboricola (七葉蓮)， 
S. bodinieri (川齢鴨腳木)，S. delavayi (大泡通)，S. kwangsiensis (漢桃葉）and S. 
venulosa (密月底iS掌柴）.Plants of the Schefflera genus are clinically used by Chinese 
herbal practitioners for the treatment of pain, fever, headache, rheumatic arthritis, 
bone fracture, sprains, pharyngitis, dermatitis, eczema and lumbago in Asian countries 
(Li, 1999). Many of them have been reported for their antinociceptory (Zhu et al., 
1996), anti-inflammatory (Shen et al, 1998), antiviral (Li et al., 2004), anti-malarial 
(Tetyana et al., 2002)，and antifungal activities (Muir et al,, 1982). 
Previous reports indicated that Schefflera plants exhibit anticancer activities. Kuo 
and colleagues reported that the ethyl acetate fraction of S. taiwaniana exhibited 
significant growth inhibitory activity in four human cancer cell lines, hepatoma (59T), 
colon cancer (DLDl) , nasopharyngeal carcinoma (HONEl) , and gastric cancer 
(SCMl) (Kuo et al., 2002). Besides, the saponins isolated from S. fagueti showed 
significant inhibitory effects on three cell lines, hybridoma (J774), human kidney 
cancer cells (HEK-293), and fibrosarcoma (WEHI-164) (Cioffi et al, 2003; Braca et 
al” 2004). In particular, betulinic acid (BA) has demonstrated selective cytotoxicity 
over a number of specific tumor types and its anticancer activity was confirmed in 
mice bearing human xenografts (Zuco et al” 2002; Eiznhamer and Xu, 2004). This 
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compound is currently undergoing preclinical development for the treatment or 
prevention of a number of malignant tumors. 
Schefflera octophylla (Lour.) Harms, is one of the best-known native tree species 
in Hong Kong. It is instantly recognizable by its palmately compound leaves, with 5 
to 10 leaflets radiating from the end of the stalk. However, in 1990, David Frodin 
reported that the tree should actually be called S. heptaphylla (L.) Frodin. (Frodin, 
1990). It is one of the principal ingredients of the herbal tea 'Twenty-four items tea' 
(二十四味 ) ’ which is widely used for the treatment of common cold in Hong Kong. 
The antiviral activities of S. heptaphylla have been reported (Li et al., 2004). However, 
its anticancer effect has not been investigated. 
Triterpenoids are compounds with a carbon skeleton based on 6 isoprene units 
which are widely found throughout the plant kingdom. They have relatively complex 
cyclic structures, most being alcohols, aldehydes, or carboxylic acids. Thousands of 
structures have been reported with hundreds of new derivatives described each year. 
Triterpenoids and their glycosides, called saponins, are the major chemical 
constituents of S. heptaphylla. These triterpenoids and their glycosides can be divided 
into different types according to their structures, including lupane-type, ursane-type 
and oleanane-type (Sung and Adam, 1991a; Sung et al., 1991c; Sung et al” 1992; 
Tran and Adam, 1992; Maeda et al., 1994). Three triterpenoids have been isolated 
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from S. heptaphylla (Sung et al” \99\b). They are betulinic acid, 
3a-hydroxy-lup-20(29)-ene-23,28-dioic acid, and 3a, 11 -a-dihydroxy-lup-20(29)-ene-
23,28-dioic acid. The structures of 3a-hydroxy-lup-20(29)-ene-23,28-dioic acid and 
betulinic acid are the same except the methyl group of betulinic acid at carbon-23 is 
replaced by a carboxyl group in 3a-hydroxy-lup-20(29)-ene-23,28-dioic acid (Fig. 
1.1). However, the bioactivities of this triterpenoid have not been investigated. 
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Molecular formula of C30H46O5 
MW: 486.33 
BA: RI = H, R2 = H, R3 = CH3, R4 = H 
Molecular formula of C30H48O3 
MW: 456.36 
Fig. 1.1 Chemical structures of 3a-hydroxylup-20(29)-ene-23,28-dioic acid 
(HLDA) and betulinic acid (BA) 
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1.2.7 Anticancer activities of triterpenoids 
Triterpenoids have been tested for a variety of biological activities. It is shown 
that many triterpenoids possess a number of intriguing pharmacological effects 
including anticancer activity. 
Previous reports indicated that betulinic acid is a melanoma-specific cytotoxic 
triterpenoid (Pisha et al., 1995). Betulinic acid induced cell cycle arrest at Gi phase 
and caused apoptosis in human melanoma (B16F10) cells (Sawada et al., 2004). 
Other studies showed that betulinic acid triggers apoptosis in human colorectal 
carcinoma (HCT 116) and prostate carcinoma (DU145) by a direct effect on 
mitochondria through caspase-3 activation (Fulda et al., 1998). 
F035, a triterpenoid saponin, and two pure biologically active derivatives from 
Acacia victoriae, an Australian desert tree of the Leguminosae family, markedly 
inhibited the growth of several tumor cell lines with minimum growth inhibition in 
human foreskin fibroblasts, mouse fibroblasts, and immortalized breast epithelial cells. 
The triterpenoid saponins induce cell cycle (Gi) arrest in human breast cancer 
(MDA-MB-453) and apoptosis in Jurkat cells (T-cell leukemia) (Mujoo et al, 2001). 
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1.2.8 Cancer and apoptosis 
There are two major mechanisms of cell death, necrosis and apoptosis. Necrosis, 
frequently initiated by damage to the plasma membrane, represents a passive form of 
cell death induced mainly by non-physiological agents and is often accompanied by 
autolysis of the cell. In contrast, apoptosis is a cell suicide mechanism which is 
important in controlling cell number and proliferation as part of normal development. 
It is defined by a stereotypical series of biochemical and morphological changes, 
including cell shrinkage, chromatin condensation, nuclear fragmentation, membrane 
blebbing, caspase activation, and the formation of membrane bound vesicles termed 
as apoptotic bodies (Hengartner, 2000). Apoptotic cells are rapidly eliminated by 
phagocytic cells without eliciting a significant inflammatory damage to surrounding 
cells (Kerr et al, 1972). 
Apoptosis, or programmed cell death, is a key regulator of tissue homeostasis, 
which critically depends on the balance between cell proliferation and cell death, 
(Evan and Vousden, 2001). Apoptosis induction is one of the important anticancer 
therapeutic routes because nearly all anticancer approaches, such as anticancer drugs, 
y-irradiation or immunotherapy, act primarily by inducing apoptosis in target cells 
(Ghobrial et aL, 2005; Lockshin and Zakeri, 2004). Thus, apoptotic regulation is a 
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critical determinant of carcinogenesis and the therapeutic responsiveness of cancers 
(Konstantinidou et aL, 2002; Sun et al, 2004). 
This mode of cell death engages well-ordered signaling cascades, in which loss 
of mitochondrial membrane potential through the action of the Bcl-2 family of 
proteins, caspase activation, and DNA fragmentation are the hallmarks (Strasser et aL, 
2000). The apoptotic pathways can be initiated from different entry sites. For example, 
active signaling can be initiated from death receptors, such as CD95 and TRAIL 
receptors, or at mitochondria through actions of the Bcl-2 family proteins (Fig. 1.2). 
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Fig. 1.2 A simplified diagram showing the extrinsic and intrinsic pathways of 
apoptosis. Apoptosis occurs through two main pathways. The extrinsic pathway is a 
receptor-linked pathway that is initiated by ligand binding to death receptors on the 
cell surface. Alternatively, the intrinsic pathway is mediated through changes in 
mitochondrial membrane potential and release of apoptogenic molecules such as 
cytochrome c from the mitochondria, which is controlled by the Bcl-2 family proteins. 
(Modified from Philchenkov, 2004 and Wang et al.’ 2000) 
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1.2.8.1 The Apoptosis Pathways 
The apoptosis pathways can be initiated by different entry sites and assigned to 
two categories for simplicity, the extrinsic and intrinsic pathways. The extrinsic 
pathway is a receptor-linked pathway that is initiated by ligand binding to a receptor 
on the surface of the cell, such as CD95 and TRAIL receptors. On the other hand, the 
intrinsic pathway is mediated through changes in mitochondrial membrane potential. 
Several pathways of apoptosis had been described, and the pathways elicited are 
highly dependent on cell type and the apoptotic stimuli. Hundreds of proteins are 
involved in the molecular signal transduction of apoptosis (Hengartner, 2000). Among 
them, the Bcl-2 family members, cytochrome c and apoptosis protease activation 
factor-1 (Apaf-1) are found extremely important in apoptosis that elicited by 
chemotherapeutic drugs. Cystein aspartate-specific proteases, also known as caspases, 
are another important family of intracellular proteins involved in the initiation and 
execution of apoptosis (Cohen, 1997; Earnshaw et al., 1999). 
Caspases 
Mechanisms associated with caspase activation in the extrinsic and intrinsic 
apoptotic pathways have been characterized extensively (Hengartner, 2000; Ghobrial 
et al., 2005). Both apoptotic cascades are activated in response to a wide variety of 
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Stimuli including stress, cytotoxic drugs, ionising radiation, and withdrawal of 
survival factors (Zabkiewicz and Clarke, 2004). 
Caspases can be subdivided into two general categories: initiator caspases and 
effector caspases. The effector caspases, including caspases 3，6 and 7, are those that 
attack critical cytoplasmic proteins like cytoskeletal proteins, polyadenosylribose 
polymerase, and other strategic enzymes or structural proteins. The effector caspases 
typically exist as proenzyme in the cytoplasm and are proteolytically activated by the 
initiator caspases, including caspases 8, 9 and 10 (Fulda and Debatin, 2004). Usually, 
initiator caspases, once activated, will activate the downstream effector caspases in a 
cascade-like pattern (Slee et al., 1999; Thornberry and Lazebnik, 1998). Caspases can 
activate each other by cleavage at identical sequences, resulting in amplification of 
caspase activity through a protease cascade (Thornberry and Lazebnik, 1998). In turn, 
the downstream effector caspases cleave a number of different substrates in the 
cytoplasm or nucleus, contributing to morphological and biochemical alterations and 
characteristics of apoptosis. For example, poly(ADP-ribose)polymerase (PARP), 
mitogen-activated protein kinase/ERK kinase kinase (MEKK), DNA fragmentation 
factor (DFF), and others (Cohen, 1997; Fulda and Debatin, 2004). Likewise, 
proteolysis of several cytoskeletal proteins such as actin (Mashima et al., 1997)， 
fodrin (Janicke et al,, 1998), and lamin (Orth et aL, 1996) may initiate morphological 
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alterations observed during apoptosis including cell shrinkage, loss of cell-matrix and 
cell-cell interactions and formation of apoptotic bodies. 
PARP is localized to the centrosomes and the chromosomes. It is a nuclear 
enzyme that is activated by DNA strand breaks. Once activated, it is actively involved 
in DNA repair. At physiological conditions, PARP plays an important role in 
maintaining genomic stability, controlling homologous recombination, and regulating 
centrosome function (Kanai et aL, 2000; Tong et aL, 2001). PARP activation usually 
results from caspase-3 activation (Cryns and Yuan, 1998), no matter in animal or plant 
cells, although some studies reported that PARP cleavage can also be stimulated by 
caspase-7 (Germain et aL, 1999). 
Bcl-2 family proteins 
The Bcl-2 family proteins are the central regulator of apoptosis. It comprises 
both antiapoptotic and proapoptotic members. The expression ratio of proapoptotic to 
antiapoptotic members is critical to the cellular decision to live or die (Herzig and 
Christofori, 2002). 
Antiapoptotic members of the family (e.g. Bcl-2, BC1-XL, BOO and Bcl-w) inhibit 
apoptosis and promote cell growth. On the other hand, the proapoptotic members (e.g. 
Bax, Bak, Bok) promote apoptosis and drive cell to die (Cory and Adams, 2002). It 
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has been suggested that the antiapoptoic Bcl-2 family members function, at least in 
part, by interacting with and antagonizing proapoptotic family members (Opferman 
and Korsmeyer, 2003). Imbalanced expression among the Bcl-2 family of proteins, in 
favor of the antiapoptotic members, is a phenomenon frequently occured in cancer 
cells. Overexpression of Bcl-2, BC1-XL or other antiapoptotic homologues occurs in 
more than half of all cancers (Kabore et al” 2004; Osford et al, 2004). Moreover, loss 
of proapoptotic Bax and Bak is also a common feature in human tumors (Meijerink et 
al, 1998). 
The proapoptotic Bcl-2 homologues Bax and Bak are inserted in the outer 
mitochondrial membrane upon their oligomerization, thus forming new channels and 
enlarging the existing permeability transition pore. This promotes cytochrome c 
release from the mitochondria (Borner, 2003). The antiapoptotic family members like 
Bcl-2 and BC1-XL hold Bax and Bak in check, possibly by forming heterodimers with 
these molecules, thereby preserving mitochondrial integrity. 
The Extrinsic death receptor pathway 
The extrinsic pathway is a receptor-linked pathway that is initiated by ligand 
binding to the death receptors of the tumor necrosis factor (TNF) receptor superfamily, 
which includes members such as CD95 (APO/Fas) or TRAIL receptors. The death 
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receptors of the tumor necrosis factor receptor (TNFR) superfamily such as Fas and 
TRAIL receptors share a distinct domain within their cytoplasmic tails called death 
domain (Garg and Aggarwal, 2002). When Fas ligand (FasL) binds to and induces 
clustering of Fas, activation of these receptors results in the recruitment of several 
intracellular proteins like Fas-associated death domain (FADD) and procaspase-8 to 
form the death-inducing signaling complex (DISC), and caspase-8 is thus activated 
(Ashkenazi, 2002). 
Upon cleavage of procaspase-8 and subsequent activation, caspase-8 can then 
initiate the proteolytic activation of caspase-3 and caspase-7 that eventually leads to 
apoptosis. The extrinsic and intrinsic apoptotic pathways can be interconnected at 
different levels. Caspase-8 can either directly cleaves and activates the effector 
caspase-3 in type I cells or cleave the Bid in type II cells (Scaffidi et al., 1999; 
Barnhart et al., 2003). A mitochondrial amplification loop can be initiated by 
caspase-8-mediated cleavage of Bid in response to death receptor activation. The 
truncated Bid (tBid) translocates to the mitochondria and leads to the oligomerization 
of Bax and Bak that eventually initiated the intrinsic apoptosis pathway (Wei et al., 
2000). 
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Intrinsic mitochondrial pathway 
The intrinsic pathway, on the other hand, involves activation of the proteolytic 
caspases in the cytosol by the apoptogenic molecules released from mitochondria, 
under the control of the Bcl-2 family proteins (Gross et al,, 1999). Under apoptotic 
stimuli, mitochondria become permeable due to the loss of mitochrondrial membrane 
potential, which in turn release apoptogenic factors such as cytochrome c, 
apoptosis-inducing factor and/or endonuclease G from the mitochondrial 
intermembrane space (van Loo et al, 2002). Some of the proapoptotic Bcl-2 proteins, 
such as Bax, Bak and Bid, normally reside in the cytosol but translocate to 
mitochondria upon the apoptotic stimuli, where they promote release of the 
apoptogenic molecules (Antonsson et al, 2000). However, their proapoptotic 
activities can be antagonized by the prosurvival Bcl-2 family proteins such as, Bcl-2 
and BC1-XL (Oltvai et al., 1993). The released cytochrome c then associates with the 
apoptotic-protease-activating factor-1 (Apaf-1) and procaspase-9, together with dATP 
or ATP, to form a structure called apoptosome (Cain et al., 2002). The initiator 
caspase-9 is thus activated within the apoptosome, which then cleaves and activates 
effector caspase-3, -6 and -7 (Zhivotovsky，2003). The activated effector caspases 
then cleave their corresponding death substrates such as PARR Cleavage of the target 
proteins results ultimately in apoptotic cell death (Cohen, 1997). As mentioned before, 
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the extrinsic and intrinsic apoptotic pathways can be interconnected at different levels, 
and a mitochondrial amplification loop can be initiated by caspase-8-mediated 
cleavage of Bid in response to death receptor activation. Truncated Bid (tBid) then 
induces Bax and Bak to oligomerize (Wei et aL, 2000), which in turn triggers the 
release of apoptogenic factors. The intrinsic pathway is therefore activated. 
1.2.9 Studies of anticancer molecules against melanoma 
Melanoma is extremely resistant to chemotherapeutic drugs, and the apoptotic 
indices are typically low in melanoma tumors (Staunton and Gaffney, 1995). Thus, 
identification of molecules involved in the regulation and execution of apoptosis is 
important for treating melanoma. 
1.2.9.1 In vitro models for studying anticancer molecules 
Tissue culture-based experiments are important to elucidate many of the 
autonomous changes in cancers and to study the therapeutic mechanisms of anticancer 
drugs. Due to the ease of establishment and maintenance, in vitro models are 
attractive especially for screening purposes (Voskoglou-Nomikos et aL, 2003). 
Screening for anti-cancer substances is commonly conducted using viability 
assays (Hagg et al., 2002). The present human tumor cell line in vitro screen is 
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technically simple, relatively fast, cheap, reproducible, and provides valuable 
indicative data of mechanistic activity and target interaction (Suggitt and Bibby, 
2005). 
Cell-based assays are particularly valuable compared with cell-free assays when 
searching for therapeutic agents. Because they select not only for activity against a 
particular target but also for other properties, such as the permeability to cells and the 
activity of the agent to retain in tissue culture medium and in cells (Roberge et al, 
2000). However, the limitations of in vitro method do exist. An inherent problem with 
this approach is that all compounds that are toxic and growth inhibitory, irrespective 
of mechanism of action, will score positive. It would be beneficial to be able to screen 
for compounds that specifically induce apoptosis (Hagg et al, 2002). It is also clear 
that factors other than the inherent chemosensitivity of tumor cells significantly 
influence the outcome of chemotherapy in vivo (Suggitt and Bibby, 2005). 
Assays for measuring anticancer activity in vitro 
Cell density, viability, proliferation status and metabolic activity are the most 
important parameters to assess the efficacy of drugs in cell-based anticancer research. 
Several assays have been developed targeted to measure these parameters. 
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Trypan blue exclusion is the most widely accepted method for enumerating 
living and dead cells in culture. Trypan blue will penetrate and stain dead cells that 
have lost membrane integrity. On the contrary, the dye will be excluded by the viable 
cells with intact cell membranes. Thus, the viability and cell density can be 
determined simultaneously by direct counting of cells with the aid of hemacytometer. 
A relatively simple, indirect, colorimetric method for the quantitative 
measurement of surviving cells was introduced by Mosmann in 1983, which was 
named as MTT assay. The assay is based on the capacity of mitochondrial 
dehydrogenase enzymes of viable cells to transform the yellow, water-soluble 
tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
into its blue, water-insoluble formazan derivative (Mosmann, 1983). A linear 
relationship was demonstrated between the formazan products and the number of 
viable cells (Ferrari et al.’ 1990). Because of its high sensitivity and reproducibility, it 
was widely used to monitor the sensitivity of human tumor cells to chemotherapeutic 
agents (Cole, 1986). Since the process of apoptosis is complex and not single feature 
can distinguish between apoptosis and necrosis, both flow cytometry and western blot 
techniques were therefore used in our study to confirm the mode cell death induced by 
HLDA and the ethyl acetate fraction. Flow cytometry has been applied in basic 
research and in the clinic to identify and measure apoptotic cells. Flow cytometry is 
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an innovative technology which involves the use of a beam of laser light projected 
through a liquid stream that contains cells. The signals produced are then converted 
for computer storage and data analysis, and can provide information about various 
cellular properties (Culmsee and Nolte，2002). The apoptotic cells, but not necrotic 
ones, have reduced DNA stainability following staining with a variety of 
fluorochromes such as propidium iodide (PI) (Darzynkiewicz et aL, 1992). Therefore, 
the presence of cells with DNA stainability lower than that of Gi cells (i.e. sub-Gi 
peak) in the DNA histogram has widely been considered as a specific marker of cell 
death by apoptosis (Bertho et aL, 2000; Darzynkiewicz et aL, 1992; Nicoletti et al., 
1991). 
Western blotting is a method in molecular biology for detecting and measuring 
semi-quantitatively the expression of the protein of interest in a sample using specific 
antibody. In cancer research, this technique has been extensively used for 
investigating the alterations of protein expressions of cancer cells induced by 
anticancer agents, giving light on the possible therapeutic routes of the agent. 
Apoptosis is characterized by internucleosomal DNA fragmentation and cleavage of 
many housekeeping proteins such as poly(ADP-ribose) polymerase (PARP). PARP 
involves in DNA repair is important for cells to maintain their viability. Cleavage of 
PARP facilitates cellular disassembly and serves as a marker of cells undergoing 
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apoptosis. It is thought to be one of the earliest targets for cleavage by caspase-3-like 
proteases during apoptosis (Boulares et al” 2002). 
1.2.9.2 In vivo models for studying anticancer molecules 
Before a particular drug or procedure can be tested on human, antitumor in vivo 
studies have to be shown to be positive in laboratory animals. Mouse has been 
extensively developed as a tumor-bearing animal in the last 40 years and remains the 
animal of choice for cancer models. Since mouse and human skin share many 
characteristics, mouse models of cancer are often good approximations of human 
cancer counterparts and recapitulate the tumor-stromal interactions, angiogenesis, and 
miiltistep nature of tumor progression of cancers (Van Dyke and Jacks, 2002). The 
response of a tumor to an experimental drug is studied in the context of a living 
organism with a fully functional metabolic system and the potential to exhibit possible 
drug-related toxic effects can be studied using in vivo model (Voskoglou-Nomikos et 
al., 2003). Thus, these models will likely aid in the development and testing of novel 
therapeutic approaches. In the 1950s, spontaneously arised or chemically induced 
tumors of mice were used. Transplantation of human tumors in mice became possible 
with the development of technologies for creating immunocompromised mice and 
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with the discovery of nude mice (Voskoglou-Nomikos et al,, 2003). These models aid 
in the development and testing of novel therapeutic approaches. 
Chemically induced skin carcinogenesis model to study cancer preventive effect 
Using chemical carcinogens to induce squamous lesions in rodents has been 
extensively characterized (Yuspa and Poirer, 1988). Most commonly, a two-step 
process is used with 7,12-dimethylbenz[a]anthracene (DMBA) as the initiator and 
12-0-tetradecanoylphorbol-13-acetate (TPA) as promoter. Typically 
papillary/polypoid exophytic squamous lesions (papillomas) arise first (Klein-Szanto 
et al, 1994). Squamous papillomas with a craterlike growth pattern and a polypoid 
stalk are very common in mice treated with chemical carcinogens. 
Chemoprevention is the use of agents to slow down the progression of, reverse, 
or inhibit carcinogenesis, thereby lowering the risk of developing invasive or 
clinically significant disease. Because the initiation and progression phases are 
irreversible and are relatively transient events, the promotion phase of carcinogenesis 
may provide the best target for cancer prevention (Sun et al., 2004). The occurrence 
and development of tumors may be prevented and blocked if some effective 
interference factors are brought into play. 
Skin carcinogenesis can be operationally and mechanistically divided into at 
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least three major stages, initiation, promotion and progression. The multistage model 
of mouse skin carcinogenesis has been extremely useful for studying various factors 
that modify the carcinogenic process (Slaga et al” 1996). It is also an ideal system to 
study the timing of qualitative and quantitative alterations which takes place during 
the different stages of chemical carcinogenesis, allowing analysis of the events that 
lead to the transition from the stage of initiation to the stage of promotion and finally 
to the progression of carcinogenesis (Murakami et al., 2004; Zoumpourlis et al, 2003). 
Most commonly, a two-step process is used by using DMBA as the initiator and TPA 
as the promoter (Owens et al., 1999; Bai et al,, 2004; Ding et al, 2004). Using the 
DMBA/TPA model system, one can specifically study the effects of potential 
modifiers on the initiation and the promotion stages independently (DiGiovanni, 
1991). For these advantages, the DMBA/TPA model was chosen in this study to 
investigate the cancer preventive effects of the ethyl acetate fraction in vivo. 
Human xenograft model to study cancer therapeutic effect 
Congenitally athymic nude mice (nu/nu) are presented as a model for the study 
of cell-mediated immunologic deficiencies. These mice possess a vestigial thymus 
which is incapable of producing mature T-cells as shown by a decreased lymphocyte 
population carrying the theta antigen and depleted 'thymus-dependent' areas in their 
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peripheral lymphoid organs (Pelleitier and Montplaisir, 1975). They have been used in 
recent years to study the biology of human tumors and to assess the therapeutic 
responses in vivo because their compromised immune system makes them impossible 
to reject foreign cells (called xenografts). The first human xenograft was created in 
1969 (Rygaard and Povlsen, 1969)，in which the xenografts were implanted 
subcutaneously into the immunosuppressed mice. This model has then played a 
significant role in preclinical anticancer drug development for the past 25 years 
(Brady et al., 2002; Kelland, 2004). Their use as a predictive indicator of probable 
clinical activity has been validated for cytotoxicity. Efficacy of the drug in the human 
xenograft models can be measured in terms of tumor size or animal survival (Kerbel, 
2003). Differences in tumor size between treated (T) and control (C) groups of 
aminals are most commonly expressed by the percent change in tumor size (T/C%) or 
percentage of growth inhibition (100% - T/C%). 
33 
Chapter 2 Materials and methods 
Chapter 2 
Materials and Methods 
2.1 Phytochemicals 
The pure compound 3a-hydroxylup-20(29)-ene-23,28-dioic acid (HLDA) and the 
ethyl acetate fraction were prepared from Schefflera heptaphylla. They were kindly 
provided by Dr. Yaolan Li (Jinan University, Guangzhou, P. R. China). The detailed 
extraction protocols were described by Li (Li, 2005). Betulinic acid (both were 
purchased from Sigma, St. Louis, MO) were used in this study as a comparison of the 
antiproliferative activities of HLDA and the ethyl acetate fraction. The chemical 
structures of HLDA and betulinic acid were shown in Fig. 1.1. 
2.2 Chemicals, Cell Lines and Culture Conditions 
All the chemicals and culture media were purchased from Sigma, unless otherwise 
stated. Six cell lines of different liistotypes were used in this study. They included A375, 
human melanoma cells; HEp2, human laryngeal carcinoma cells; HepG2, human 
hepatocellular carcinoma cells; MCF-7，human breast carcinoma cells; PC-3, human 
prostate carcinoma cells and Vero，monkey normal kidney cells. All the cell lines were 
obtained from American Type Culture Collections (ATCC), Rockville, MD. A375, 
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HEp2 and Vero cells were maintained in Dulbecco's modified Eagle's medium; HepG2 
and MCF-7 cells were maintained in RPMI 1640 medium, and PC-3 was maintained in 
F12K medium. All media were supplemented with 0.2% sodium bicarbonate, 10% 
heat-inactivated fetal bovine serum, 100 U/ml of penicillin, and 100 |ig/ml of 
streptomycin (all from Gibco-BRL, Gaithersburg, MD). All cell lines were kept under a 
fully humidified atmosphere at 37 °C in 5% CO2. The cells were passaged two to three 
times a week in 25 cm^ tissue culture flasks (Sarstedt, Niimbrecht, Germany). Upon 
passages, the cells were detached from the flasks by treatment with 1 ml of 
Trypsin-Versene solution (containing 0.25% trypsin and 0.02% EDTA) for 1 min, and 
the reaction was then stopped by the corresponding medium. The cells were washed 
once by phosphate-buffered saline (PBS), and spinned at 514 x g for 5 min (Beckman, 
Allegra'M 6R centrifuge). The cell pellet was resuspended in the medium, and the 
number of viable cells was then counted under a hemacytometer after staining with 
0.4% trypan blue solution. Cells were generally seeded at a density of 2 x 10^ cells/ml 
for each new passage. 
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2.3 Determination of in vitro antiproliferative effects of H L D A and the ethyl 
acetate fraction from S. heptaphylla on human cancer cells 
2.3.1 MTT assay 
Effects of HLDA and the ethyl acetate fraction on the proliferation and viability of 
A375, HEp2, HepG2, MCF-7 and PC-3 cancer cells and normal kidney Vero cells were 
determined by MTT assay. 
Stock sample solutions were prepared by dissolving HLDA and the ethyl acetate 
fraction in dimethyl sulfoxide (DMSO). The final test concentrations of the sample 
were prepared by diluting the stock solution with the corresponding culture medium 
before each experiment. The final concentration of DMSO did not exceed 0.5% in 
every experiment. To determine the antiproliferative activity and the general cytotoxic 
effects of HLDA and the ethyl acetate fraction, the cells were seeded in 96-well 
flat-bottomed microtiter plates (IWAKI, Chiba，Japan) at a density of 2.5 x 10^ viable 
cells/well/100 After 24 h, the confluent cell cultures were incubated with 0，12.5, 25, 
50 and 100 ^ig/ml of HLDA and 0，12.5, 25，50, 100 and 200 \xg/m\ of ethyl acetate 
fraction for 72 h. After treatment, the cells were incubated with 10 \x\ of freshly 
prepared MTT solution (5 mg/ml in PBS) at 37 °C for 4 h. The precipitated formazan 
was solubilized with 150 \x\ of 0.04 N HCl-isopropanol, and the optical densities at 570 
nm were determined by microplate reader. All test concentrations were done in 
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triplicate wells. The percentage inhibition of cell growth was calculated by the 
following equation: 
r ^ 
Average absorbance of treatment group 
1- X 100% 
Average absorbance of control group 
^ J 
2.4 Determination of the in vitro antiproliferative mechanisms of HLDA and the 
ethyl acetate fraction from S. heptaphylla in human melanoma A375 cells 
2.4.1 Flow cytometric analysis 
Effects of HLDA and the ethyl acetate fraction on cell cycle distribution of A375 
cells were analyzed by flow cytometer. Human melanoma A375 cells were seeded in 
25 cm^ sterile polystyrene tissue culture flasks at 2.5 x cells/ml. The cells were 
either treated with the ethyl acetate fraction or HLDA. After incubation in the absence 
or presence of the IC50 of the ethyl acetate fraction or HLDA for 72 h, 2 x 10^  A375 
cells were harvested, and washed twice with PBS. The cells were then fixed overnight 
at -20 °C in 70% ethanol. The fixed cells were washed with PBS twice, and were then 
incubated in dark for 30 min in 1 ml PBS solution, containing 1 mg/ml ribonuclease 
and 10 lag/ml propidium iodide (PI) (Sigma). The red fluorescence of DNA-bound PI in 
individual cells was measured at >625 nm, anaylsed with Beckman Coulter Epics 
XL-MCL flow cytometer (Miami, FL). Cell cycle distribution was analyzed using 
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Multicycle software (Phoenix Flow Systems, San Diego, CA) 
To study the roles of caspases in HLDA and the ethyl acetate fraction-induced 
apoptosis, A375 cells were preincubated with or without 20 ^iM of the caspase inhibitor 
for 30 mill prior to treatment with the IC50 of HLDA (i.e. 23 |ig/ml) or ethyl acetate 
fraction (i.e. 46 |ag/ml) for 72 h. The caspase inhibitors used were general caspase 
inhibitor (Z-VAD-FMK), caspase-8 inhibitor (Ac-IETD-CHO), and caspase-9 inhibitor 
(Z-LEHD-FMK) (all of them were purchased from PharMingen, San Diego, CA). The 
cells were then subjected to DNA content analysis by flow cytometry. 
2.4.2 Western blot analysis 
Effects of HLDA and the ethyl acetate fraction on expression of 
apoptosis-regulatory proteins were measured semi-quantitatively by SDS-PAGE and 
Western blot analysis. A375 cells were seeded in 25 cm^ sterile polystyrene tissue 
culture flasks at 2.5 x cells/ml. After 24 h of acclimatization, the cells were treated 
in the absence or presence of the IC50 of HLDA or the ethyl acetate fraction for 72 h. 
After treatment, 2x10^ cells were harvested for protein extraction. The cells were 
washed twice with ice-cold PBS with centrifugation at 4 °C. The cell pellet was then 
resuspended and homogenized in 49 ice-cold lysis buffer with 1 p-l protease inhibitor 
(Calbiochem, San Diego, CA). The cell lysate was then transferred to a microcentrifuge 
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tube and incubated on ice for 45 min. The cell lysate was then centrifuged for 15 min at 
4。C after the incubation. Finally, supernatant containing the cellular proteins was 
collected and frozen at -20。C. 
The protein content was measured by bicinchoninic acid (BCA) assay. One 
microliter of the cell lysate was diluted with 49 |LI1 ultrapure water in a microcentrifuge 
tube. A standard curve was prepared using 50 fil of 0, 25, 50, 100, 200 and 400 |ig/ml 
bovine serum albumin (BSA) solution. One milliliter of BCA assay working reagent, 
containing 1 ml Reagent A with 20 |LI1 Reagent B (Pierce, Rockford, IL), was then 
added to the microcentrifuge tube and incubated for 30 min at 37 °C. After the 
incubation, all the tubes were cooled to room temperature. Absorbance of each tube 
was then measured at 562 nm using Eppendorf BioPhotometer (Eppendorf, Hamburg, 
Germany), and protein content of the cell lysate was determined from the standard 
curve. 
Ten to twenty microliters of cellular proteins (30-80 ^ig) were then subjected to 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) analysis. 
The proteins were mixed with equal volume of 2x loading buffer, containing Tris-HCL, 
DTT, SDS，bromophenol blue and glycerol, in a microcentrifuge tube. The proteins 
were then denatured by incubation for 5 min at 95。C. The proteins were then cooled so 
that 30 to 80 were resolved by 13% SDS-PAGE. The resolved protiens were then 
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transferred to a Hybond™-C nitrocellulose membrane (Amersham Life Science, 
Buckinghamshire, UK). The membrane was then blocked with 0.2% Aurora® blocking 
reagent (ICN Biomedicals, Ohio, USA) or 0.5% non-fat dry milk, with 0.1% Tween-20 
solution. The blocked membrane was the incubated overnight with the primary 
antibody, including mouse monoclonal antibodies to Bcl-2 and Bax (BD Biosciecnces 
PharMingen), mouse monoclonal antibodies to caspase-8 and (3-actin (Cell Signaling 
Technology, Beverly, MA), and rabbit polyclonal antibodies to PARP，Bcl-XL, p53, 
Bid, Bak and caspase-9 (Cell Signaling Technology). 
After the incubation, the membrane was washed, and then incubated with 
horseradish peroxidase (HRP)-conjugated goat anti-mouse or goat anti-rabbit IgG 
polyclonal antibodies (Cell Signaling Technology) for 1 h, with shaking at room 
temperature. Finally, the membrane was washed, incubated with 10 ml LumiGLO 
Substrate (Cell Signaling Technology)，and then exposed to X-ray film. 
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2.5 Determination of the in vivo anticancer effects of the ethyl acetate fraction 
from S. heptaphylla 
2.5.1 Determination of cancer chemopreventive effect of the ethyl acetate 
fraction with DMBA/TPA-induced skin carcinogenesis model 
The cancer preventive effect of the ethyl acetate fraction was examined using a 
standard initiation-promotion protocol with 7,12-dimethylbenz[fl] anthracene (DMBA) 
and 12-O-tetradecanoylphorbol-13-acetate (TPA) as previously reported (Ding et al, 
2004) with some modifications. 
Seven to eight-week-old female ICR mice were obtained from the Laboratory 
Animal Service Centre (LASEC) of the Chinese University of Hong Kong. All 
experiments were performed according to the guidelines approved by the Chinese 
University of Hong Kong Animal Experimentation Ethics Committee (AEEC). The 
mice were housed in the animal house of the Department of Biology, CUHK, under 
controlled laboratory conditions in rodent microisolator cages at 25 士 2。C with a 12 h 
light/dark cycle and were fed with a standard diet and tap water ad libitum. Mice were 
allowed to acclimatize in the laboratory for one week before experiments. 
The mice were then randomly divided into six groups of 7 or 8. Dorsal skin of the 
mice was shaved with a surgical clipper one day before initiation. The mice were then 
exposed to a single dose of 300 nmol of DMBA in 200 \i\ of acetone. Seven days 
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following initiation, the mice were topically treated with 0, 0.4, 2, 4, 8 and 40 mg/ml of 
ethyl acetate fraction (in acetone) 30 min before promotion by exposure to 7.5 nmol of 
TP A in 200 |al of acetone. The ethyl acetate fraction and TP A were administered twice 
a week for a total 20 weeks. Incidence of papilloma-bearing mice and number of 
papillomas (>1 mm in diameter) were recorded once every 2 weeks. The cancer 
preventive effect of the ethyl acetate fraction was determined by comparing the 
fraction-treated groups with the untreated control group. 
2.5.2 Determination of cancer therapeutic effect of the ethyl acetate fraction with 
athymic BALB/c nude mice model 
Human melanoma A375 cells were implanted subcutaneously (s.c.) into athymic 
nude mice to study the cancer therapeutic effect of the ethyl acetate fraction. 
Male athymic mice (BALB/c, nu/nu, 7 to 8 weeks old) were obtained from the 
LASEC，CUHK. The animals were housed in Room 403 of LASEC under clean and 
controlled room conditions in sterile rodent microisolator cages at 25 士 2 °C with a 12 h 
light/dark cycle. Animals were fed with sterile rodent chow and water ad libitum and 
were acclimated in the laboratory for one week before experiment. All experiments 
were performed according to guidelines approved by the AEEC of CUHK. 
A375 cells were kept in 175 cm^ sterile tissue culture flasks and were maintained 
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under conditions as described in Section 2.2. Cells were detached from the flasks by 
treatment with 3 ml of Trypsin-Versene solution for 1 minute and the reaction was then 
stopped by DMEM medium. The cells were washed once by PBS and centrifugation at 
514 X g for 5 min. The cell pellet was re-suspended in DMEM medium, and the number 
of viable cells was then counted under a hemocytometer after staining with 0.4% trypan 
blue solution. Cell suspension with a density of 2.5 x 10^  cells/ml was prepared for 
inoculation into the nude mice. 
Five million A375 cells were inoculated subcutaneously at the back of each 
athymic nude mice. The A375 solid tumors were allowed to grow for 10 days before 
the mice were separated randomly into five groups of six. The mice were then treated 
topically with 0，2，4，8 and 40 mg/ml of ethyl acetate fraction in acetone once a day for 
consecutive 10 days. After treatment, the mice were sacrificed by cervical dislocation. 
Tumors were then excised and measured in term of weight by an electronic 
balance. The inhibitory effect of the ethyl acetate fraction on the growth of A375 tumor 
was expressed as reduction of tumor weight in the fraction-treated groups when 
compared to the untreated control group. 
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2.6 Statistical Analysis 
Except the data from animal studies, all the other data are presented as mean 士 
standard deviation (S.D.). Animal data are shown as mean 士 standard error of 
measurement (S.E.M.). Difference in means between the control and experimental 
groups was compared by Student's Mest; *;?<0.05, **p<0.01, and *** ；7<0.001. For 
caspase inhibitors analysis, variance between multiple groups was analysed by 
ANOVA, followed by Tukey's test, where p <0.05 indicates statistically significant 
difference. 
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Chapter 3 
Results 
3.1 Effects of HLDA and the ethyl acetate fraction on viability and 
proliferation of different cancer cell lines by MTT assay 
Effects of HLDA and the ethyl acetate fraction on cell viability and proliferation 
were studied in five human cell lines originated from different tissues by MTT assay. 
They included A375, melanoma cells; HEp2, laryngeal carcinoma cells; HepG2, 
hepatocellular carcinoma cells; MCF-7, breast carcinoma cells; and PC-3, prostate 
carcinoma cells. 
After 72 h incubation with HLDA or the ethyl acetate fraction, viability and 
proliferation of all the tested cancer cell lines were inhibited dose dependently (Fig. 
3.1 and Fig. 3.2). Treatment with 100 |ag/ml of HLDA suppressed the viability and 
proliferation of A375, HEp2, HepG2, MCF-7 and PC-3 cells by 78.3%, 59.5%, 84.3%, 
76.7% and 60.4% respectively, comparing to the control cells. Whereas, treatment 
with 200 |ig/ml of ethyl acetate fraction suppressed the viability and proliferation of 
A375, HEp2, HepG2, MCF-7 and PC-3 cells by 94.0%, 77.9%, 79.6%, 88.9% and 
76.1%, respectively. 
The values of 50% inhibitory concentration on the viability and proliferation of 
45 
Chapter 3 Results 
the five cancer cell lines (IC50) were subsequently estimated from the dose-activity 
plots. The results were summarized in Table 3.1. The values of IC50 for A375, HEp2, 
HepG2, MCF-7 and PC-3 cells were 23, 90，33，40 and 86 jag/ml, respectively. On the 
other hand, the IC50 values for the ethyl acetate fraction on A3 75, HEp2, HepG2, 
MCF-7 and PC-3 cells were 46, 110, 52，76 and 100 |Lig/ml, respectively. By 
comparing the IC50 values, A375 melanoma was apparently the most responsive cell 
line to the HLDA and ethyl acetate fraction treatments. 
3.2 Effects of HLDA and the ethyl acetate fraction on cell cycle and apoptosis 
in A375 cells determined by DNA flow cytometry 
Since the MTT studies showed that A375 melanoma was the most responsive 
cancer cell line to the reduction of viability and proliferation induced by HLDA or the 
ethyl acetate fraction, the associated mechanisms were further investigated in the 
cancer cell line. 
The melanoma cells were incubated in the absence or presence of 23 |ig/ml of 
HLDA or 46 |ag/ml of the ethyl acetate fraction for 72 h. Sub-Gi peak, representing 
the apoptotic cells elevated prominently in the treated cells, in comparison of the 
control cells (Fig. 3.3). The apoptotic cells were then measured, and were expressed 
as proportion of the total analyzed cells. Both HLDA and the ethyl acetate fraction, 
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induced apoptosis in the cancer cells, so that the apoptotic cells with fragmented DNA 
elevated by 24-fold and 12-fold, respectively, of the control level (Fig. 3.4). 
Besides apoptosis induction, results from the DNA-flow cytometric study also 
showed that the ethyl acetate fraction also altered cell-cycle progression of the 
melanoma cells. The extract seemed to arrest S-phase cells so that they increased from 
17.0% of the cells in cell cycle to 36.8%; G2/M cells also elevated from the control 
9.70/0 to 17.90/0. Go/Gi cells, on the other hand, decreased from 73.8% to 42.2%. 
However, HLDA did not modulate the cell-cycle progression of the melanoma cells 
significantly after 72 h of incubation. All these findings suggested that the 
fraction-induced growth inhibition on the melanoma cells seemed to be mediated by 
both apoptosis induction and cell-cycle arrestment, while the HLDA-induced growth 
inhibition was mediated by apoptosis only. 
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Fig. 3.1 Effects of HLDA on the proliferation and viability of A375, HepG2, 
HEp2, PC-3 and MCF-7 cells determined by MTT assay. Results are expressed as 
mean 士 S.D. of three independent experiments. *，** and *** represent statistical 
significance at p<0.05, p<0.01 and /7<0.001 respectively, determined by Student's 
/-test. 
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Fig. 3.2 Effects of the ethyl acetate fraction on the proliferation and viability of 
A375, HepG2, HEp2, PC-3 and MCF-7 cells determined by MTT assay. Results 
are expressed as mean 士 S.D. of three independent experiments. ** and *** 
represent statistical significance at /7<0.05, /?<0.01 and /><0.001 respectively, 
determined by Student's "test. 
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Table 3.1 The values of 50% inhibitory concentration (IC50) of the ethyl acetate 
fraction and HLDA on the viability and proliferation of A375, HEp2, HepG2, 
MCF-7 and PC-3 cells. 
IC5o(^g/ml) 
Cell line Histotype 
Ethyl acetate fraction HLDA 
A375 Melanoma 46 23 
HEp2 Laryngeal carcinoma 110 90 
HepG2 Hepatocellular carcinoma 52 33 
MCF-7 Breast carcinoma 76 40 
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Fig. 3,4 Effects of HLDA and the ethyl acetate fraction on cell cycle and 
apoptosis in A375 cells. Numeric data showing the effects of HLDA and the ethyl 
acetate fraction on cell cycle and apoptosis in A375 cells measured by flow cytometer 
after incubation with the IC50 of HLDA or the IC50 of the ethyl acetate fraction for 72 h. 
The melanoma cells were treated for 72 h, either in the absence, i.e. control (blue bars) 
or in the presence of HLDA (yellow bars) or the ethyl acetate fraction (green bars). The 
apoptotic cells were measured using the control software of the flow cytometer, and 
were expressed as proportion of the total analyzed cells. Both HLDA and the ethyl 
acetate fraction elevated sub-Gior apoptotic cells prominently. The cells in different 
cell cycle phase were expressed as proportion of the cells in cell cycle. In addition, the 
ethyl acetate fraction elevated the cells in S and G2/M phases whereas HLDA did not. 
*/?<0.05 and **/7<0.01, compared to the control level by Student's M;est. 
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3.3 Effects of HLDA and the ethyl acetate fraction on apoptosis induction in 
A375 cells determined by Western blotting 
Induction of apoptosis in the melanoma cells by HLDA and the ethyl acetate 
fraction were further investigated by the western-blot study that PARP was cleaved at 
72 h treatment. PARP [poly(ADP-ribose) polymerase] is an enzyme that is involved in 
DNA repair and genomic maintenance. Besides indicating the occurrence of apoptosis, 
cleavage of PARP also suggests the activation of proteolytic caspases in the cell death 
process. During the execution phase of apoptotic cell death, proteolysis of the intact 
form of PARP (cleaved from 116 kDa into 89 kDa) results in the loss of normal PARP 
function, which facilitates cellular disassembly. As shown in Fig. 3.5, after 72 h 
incubation with HLDA or the ethyl acetate fraction, PARP cleavage was observed in 
the treated cells, in comparison to the intact PARP in the control cells. Results from the 
immunoblot suggest that either HLDA or the ethyl acetate fraction induces apoptosis in 
the melanoma cells possibly via activation of caspases. 
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Fig. 3.5 Representative immunoblot showing the effects of HLDA and ethyl 
acetate fraction on PARP protein. PARP cleavage from 116 kDa to 89 kDa was 
observed at 72 h treatment with HLDA or the ethyl acetate fraction, suggesting that 
apoptosis was induced in the melanoma possibly via activation of caspases. p-actin was 
included as loading control to normalize expressions of the PARP protein. 
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3.4 Effects of H L D A and ethyl acetate fraction on caspases in A375 cells 
As mentioned in Section 3.2, the apoptotic peaks generated in the HLDA and the 
ethyl acetate fraction-treated cells (Fig. 3.3) were associated with cleavage of PARP 
(Fig. 3.5), implying the possible involvement of caspases in the cell death mechanisms 
since PARP is one of the substrates of caspase-3 (Boulares et al., 2002). To find out 
which caspases had been involved, lysates from the HLDA- and the fraction-treated 
A375 cells were immunoblotted with specific antibodies against caspase-8 and 
caspase-9, which are the initiator caspases of the extrinsic and the intrinsic apoptotic 
pathways, respectively. As shown in Fig. 3.6a, processing of procaspase-8 into the 
active p43 and p41 subunits was more prominent in HLDA- and the fraction-treated 
A375 cells than in the control cells. Similarly, cleavage of procaspase-9 into active p37 
and p35 fragments was evident upon treatment with either HLDA or the fraction (Fig. 
3.6b). These data suggested that both the extrinsic and the intrinsic apoptotic pathways 
had been elicited by HLDA and the ethyl acetate fraction in the A375 cells. 
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Fig. 3.6 Representative immunoblots showing the effects of H L D A and the ethyl 
acetate fraction on caspase-8 and caspase-9. Lysates from the HLDA- and the 
fraction-treated A375 cells were analysed for caspases by Western blotting. Cleavage 
of caspase-8 and caspase-9 into their active subunits was observed in both the HLDA-
and the fraction-treated cells. P-actin was included as loading control. 
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3.5 Effects of caspase inhibitors on the HLDA- and the ethyl acetate 
fraction-induced apoptosis in A375 cells 
To verify the roles of caspases in the HLDA- and the ethyl acetate 
fraction-induced apoptosis, A375 cells were preincubated with the general caspase 
inhibitor (GCI; Z-VAD-FMK), caspase-8 inhibitor (C8I; Ac-IETD-CHO) or caspase-9 
inhibitor (C9I; Z-LEHD-FMK) prior to the treatment with HLDA or the fraction. 
As shown in Fig. 2).la-c and Fig. 3.8, the HLDA-induced apoptosis in A375 was 
completely retarded by preincubation with GCI, suggesting that the HLDA-induced 
apoptosis was executed solely by the caspase-dependent events. In contrast, 
preincubation with GCI could only partially inhibit the ethyl acetate fraction-induced 
apoptosis (Fig. 3.9a-c and Fig. 3.12), suggesting some of the apoptotic cells were 
resulted from caspase-independent events. 
As shown in Fig. 3.1d&e and Fig. 3.8, the HLDA-induced apoptosis in A375 cells 
was partially inhibited after preincubation with C8I or C9I, indicating that caspase-8 
and -9 had been playing important roles in the HLDA-induced apoptosis. On the 
contrary, the apoptosis induced by the ethyl acetate fraction could only be retarded by 
caspase-8 or caspase-9 inhibitor to a lesser extent, suggesting that the initiator caspases 
had played lesser significant functions in the cell death process (Fig. 3.9d&e and Fig. 
3.10). 
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Fig. 3.7 Representative DNA histograms showing the effects of different caspase 
inhibitors on HLDA-induced apoptosis. 
Human A375 cells were preincubated with or without different caspase inhibitors for 
30 min prior to treatment with HLDA for 72 h. The cells were then subjected to 
DNA-flow cytometry analysis. 
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Fig. 3.8 Effects of preincubation with different caspase inhibitors on 
HLDA-induced apoptosis in A375 cells 
A375 cells were preincubated with or without different caspase inhibitors prior to the 
addition of HLDA. The cells were then subjected to DNA-flow cytometry analysis. The 
percentage of sub-Gi cells (i.e. apoptotic cells) are presented numerically and are 
expressed as mean 土 S.D. Data were analysed by ANOVA, followed by Tukey's test. 
Bars with the same letter indicate no significant differences (p>0.05). 
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Fig. 3.9 Representative DNA histograms showing the effects of preincubation 
different caspase inhibitors on the ethyl acetate fraction-induced apoptosis. 
Human A375 cells were preincubated with or without different caspase inhibitors for 
30 min prior to treatment with the ethyl acetate fraction for 72 h. Cells were then 
subjected to DNA-flow cytometry analysis. 
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Fig. 3.10 Effects of preincubation with different caspase inhibitors on ethyl 
acetate fraction-induced apoptosis in A375 cells 
A375 cells were preincubated with or without different caspase inhibitors prior to the 
addition of the ethyl acetate fraction. Cells were then subjected to DNA-flow cytometry 
analysis. The percentage of sub-Gi cells (i.e. apoptotic cells) are presented numerically 
and are expressed as mean 士 S.D. Data were analysed by ANOVA, followed by 
Tukey's test. Bars with the same letter indicate no significant differences (p>0.05). 
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3.6 Effects of H L D A and the ethyl acetate fraction on the expression of Bcl-2 
family proteins in A375 cells 
As described in Section 3.2 and 3.3, both HLDA and the ethyl acetate fraction 
were capable of inducing apoptosis in A375 cells. To explore the mechanisms 
governing the HLDA- and the ethyl acetate fraction-driven apoptosis, modulations of 
Bcl-2 family protein expressions were first investigated by Western blot analysis. 
Five better-characterized Bcl-2 family proteins were studied, including the 
proapoptotic Bax, Bak and Bid, as well as the antiapoptotic Bcl-2 and BCI-XL. AS 
shown in Fig. 2).\\a-c, neither HLDA nor the ethyl acetate fraction modulated level of 
the proapoptotic Bcl-2 family proteins tested in this study. On the other hand, both 
HLDA and ethyl acetate fraction depleted level of the antiapoptotic BC1-XL (Fig. 3.1 le). 
Interestingly, another antiapoptotic member, Bcl-2, was only depleted by the ethyl 
acetate fraction, but not by HLDA (Fig. suggesting that the ethyl acetate 
fraction may contain molecules other than HLDA that have additional modulatory 
effect. 
Taken together, these results indicate that HLDA and the ethyl acetate fraction act 
at least partially by decreasing the ratio of antiapoptotic to proapoptotic protein 
expression in A375 cells, through depletion of Bcl-2 and BCI-XL. This may be one of 
the possible mechanisms to address the capability of HLDA and the ethyl acetate 
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fraction from S. heptaphylla to induce apoptosis in A375 cells. 
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Fig. 3.11 Representative immunoblots showing the effects of H L D A and the ethyl 
acetate fraction on expression of Bcl-2 family proteins. Human melanoma A375 
cells treated with or without HLDA or the fraction were analysed for Bcl-2 family 
protein expression by Western blotting, p-actin was included as loading control. HLDA 
did not modulate protein level of Bax, Bak, Bid and Bcl-2, while BC1-XL protein was 
significantly depleted. On the other hand, levels of BC1-XL and Bcl-2 were depleted 
after treatment with the ethyl acetate fraction. 
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3.7 Chemopreventive effect of the ethyl acetate fraction from S. heptaphylla on 
the DMBA/TPA-induced skin carcinogenesis model 
Results from the in vitro studies revealed a profound antiproliferative effect of the 
ethyl acetate fraction on A375 melanoma cells. Those promising data provided a solid 
foundation for further studies of its anticancer activities in animal models. Thus, the 
cancer preventive activity of the ethyl acetate fraction from S. heptaphylla was first 
studied in the DMBA/TPA-induced skin carcinogenesis model. The carcinogenesis was 
initiated by a single dose of DMBA and promoted by repeated applications with the 
tumor promoter TPA. 
Fig. 3.12 shows three representative mice from each group. As clearly depicted in 
the photographs, papillomas on the mice of the control group grew tremendously and 
were well vascularized, whereas those on the mice of the fraction-treated groups were 
growth-arrested and desiccated, or even not found at all. 
The mortality rate and the papilloma incidence of mice in the control and 
treatment groups are summarized in Table 3.2. For the entire period of treatment, no 
mice were found dead, indicating that the ethyl acetate fraction is relatively safe when 
used topically. Treatments with low doses and high doses of the ethyl acetate fraction 
were led to dramatic decreases in both the number of papilloma-bearing mice and the 
number of papilloma on mice. Surprisingly, the ethyl acetate fraction was capable of 
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completely retarding papilloma development in the group that received the dose of 40 
mg/ml. Moreover, the papilloma incidence-time plot showed that the ethyl acetate 
fraction retarded the papilloma growth dose-dependently (Fig. 3.13). 
66 
Chapter 3 Results 
(a) Control group (d) 4 mg/ml 
m圓 
(b) 0.4 mg/ml (e) 8 mg/ml 
！國d 
‘ K I H H B I H H H H • H ^ ^ H Q H H H i l 
(c) 2 mg/ml (f) 40 mg/ml 
M國 
Fig. 3.12 Photographs showing representative ICR mice treated with different 
dosages of the ethyl acetate fraction. In this DMBA/TPA-induced skin carcinogenesis 
model, skin papilloma development was initiated on the back of ICR mice by a single 
dose of DMBA. The promotion stage of the carcinogenesis was performed by repeated 
applications of TPA for 20 weeks. During the promotion period, the mice were 
topically treated with different concentrations of the ethyl acetate fraction 30 min after 
TPA application. 
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Fig. 3.13 Effect of the ethyl acetate fraction on papilloma development in the 
DMBA/TPA model. Number of papillomas (>1 mm) was recorded every 2 weeks 
starting from week 11. The results are presented as the mean number of papillomas per 
mouse 土 S.E.M. *，**, and *** represent statistically significant difference from the 
control group at /7<0.05, /?<0.01 and /7<0.001 respectively, determined by Student's 
r-test. 
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Table 3.2 Effects of different doses of the ethyl acetate fraction on DMBA/TPA 
induced papilloma development in I CR mice. The data showed were collected at the 
end of the treatment period. 
Treatments Mortality Papilloma incidence Actual dose 
(percentage of mice with applied per mouse 
papilloma development) (mg/kg) 
Control 0/15 14/15(93.3%) 0 
0.4 mg/ml 0/14 11/14(78.6%) 3.2 
2 mg/ml 0/13 12/13 (92.3%) 16 
4 mg/ml 0/16 8/16(50.0%) 32 
8 mg/ml 0/16 4/16 (25.0%) 64 
40 mg/ml 0/14 0/16 (0.0%) 320 
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3.8 Chemotherapeutic effect of the ethyl acetate fraction from S. heptaphylla on 
A375 xenograft in athymic nude mice 
Since human xenograft model is one of the best models for predicting drug 
efficacy in clinical settings (Naoe et al,, 1998), antitumor activity of the ethyl acetate 
fraction against A3 75 xenograft in athymic nude mice was examined. The mice bearing 
A375 solid tumors were treated topically with different doses of the ethyl acetate 
fraction once daily for consecutive 10 days. At the end of treatment period, the tumors 
were excised and measured for their weight and volume. Three representative mice 
from each group are shown in Fig. 3.14. The ethyl acetate fraction treatment induced 
tumor regression significantly. The fraction induced regression in the weight (Fig. 3.15) 
of the xenograft. Even at dose as low as 2 mg/ml, the tumor weight and volume were 
reduced by >70% of the control level, indicating that the ethyl acetate fraction was 
extremely effective in controlling the growth of A375 xenograft in vivo. It is 
noteworthy that a mouse was found dead in the group that received the highest dosage 
of the ethyl acetate fraction (i.e. 40 mg/ml). However, a larger sample size is required 
to confirm whether that the death was attributed to the ethyl acetate fraction treatment 
or not. 
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(a) Control (d) 8 mg/ml 
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(b) 2 mg/ml (e) 40 mg/ml 
H： ： ^ ^ I pf^^ 
,^ wlWIi li ^ ^ 
(c) 4 mg/ml 
iflH 
-i ^ j ^ y W 
Fig. 3.14 Photographs showing representative athymic mice bearing A375 solid 
tumor treated with different dosages of the ethyl acetate fraction. Athymic mice 
were inoculated with human melanoma A375 cells subcutaneously. Ten days after 
inoculation, the mice were treated topically with the different dosages of the ethyl 
acetate fraction once daily for 10 consecutive days. The A375 solid tumors were 
allowed to grow for 10 more days before sacrificed. 
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Fig. 3.15 Effect of the ethyl acetate fraction on the weight of A375 xenograft. The 
results are presented as the mean tumor weight 土 S.E.M * represents significant 
difference from the control group atp<0.05, determined by Student's 广test. 
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Chapter 4 
Discuss ion 
At present, only a few chemotherapeutic drugs are effective in the treatment of 
human cancers, mainly due to their high toxicity, lack of specificity and the rapid 
development of chemoresistance. Thus, it is important to identify new molecules with 
potential anticancer activity. Triterpenoids and their glycoside derivatives represent a 
new class of anticancer compounds with potential anticancer activity. Many of which 
have been reported as cancer-specific cytotoxic compounds (Pedersen et al., 2002; 
Sarek et al., 2003). In particular, betulinic acid, a pentacyclic triterpene, was discovered 
in 1995 as a selective inhibitor of human melanoma (Pisha et al, 1995). This 
compound is currently under preclinical evaluation in the National Cancer Institute of 
the United States. 
We have recently identified a pure compound, 
3a-hydroxy-lup-20(29)-ene-23,28-dioic acid (HLDA), from Schefflera heptaphylla in 
an antiviral study (Li et al., 2004). It was isolated for the first time from Schefflera 
heptaphylla by Adam et al (1982)，but its biological activity has never been 
documented. The chemical structure of HLDA is highly similar to that of betulinic acid, 
except the carboxyl group at carbon-28 of HLDA is replaced by a methyl group in the 
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latter (Fig. 1.1). This prompted us to investigate whether HLDA exhibits 
antiproliferative activity as well. In addition, since Kuo et al. (2002) reported strong 
anticancer activity of the ethyl acetate fraction from S. taiwaniana, the ethyl acetate 
fraction from S. heptaphylla, from which HLDA is derived, was also evaluated for its 
antiproliferative activity in this study. 
By using the MTT assay, the inhibitory activities of HLDA and the ethyl acetate 
fraction on cell proliferation and viability were evaluated in five cancer cell lines of 
different histotypes. Growth of all the cancer cells was inhibited by HLDA and the 
ethyl acetate fraction dose-dependently. A3 75 melanoma was found to be the most 
sensitive cancer cell line to the HLDA (IC50： 23 )ig/ml) and the ethyl acetate fraction 
treatment (IC50： 46 |j.g/ml), suggesting that HLDA and the ethyl acetate fraction exhibit 
certain degree of selectivity on the growth of melanoma cells, when compared to the 
other cancer cell types tested in this study. 
Little success has emerged over the last 20 years for the treatment of metastatic 
melanoma because it is often resistant to the current anticancer drugs (Tsao and Soba， 
2005). The identification of HLDA as a potent inhibitor of A375 melanoma cells may 
provide a new candidate for the treatment of melanoma-derived cancers. Thus, the 
A375 melanoma cell line was chosen for detailed analysis on the anticancer 
mechanisms of HLDA and the ethyl acetate fraction. Furthermore, their anticancer 
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activity was also evaluated in vivo. 
Triterpenes are compounds with a carbon skeleton based on 6 isoprene units and 
are found widely throughout the plant kingdom. They have relatively complex cyclic 
structures, most being alcohols, aldehydes, or carboxylic acids. Previous reports 
indicated that betulinic acid (BA)，an example of triterpenes, induced cell cycle arrest at 
Gi phase and caused apoptosis in human melanoma B16F10 cells (Sawada et al.’ 2004). 
BA also triggered apoptosis in human colorectal carcinoma HCT 116 and prostate 
carcinoma DU145 by a direct effect on mitochondria followed by caspase-3 activation 
(Fulda et al., 1998). As shown in this study, HLDA isolated from Schefflera 
heptaphylla (L.) Frodin, formerly known as Schefflera octophylla (L.) Harms, was also 
found to retard the growth of human melanoma A375 cells. 
Apoptosis induction is one of the important anticancer therapeutic routes because 
nearly all anticancer agents kill tumor cells by inducing apoptosis (Ghobrial et al., 
2005). Since the mechanisms underlying the process of apoptosis are complex and there 
is no single discriminative feature, it is necessary to use different methods to determine 
the mode of cell death. In this study, DNA fragmentation and PARP cleavage, two of 
the most commonly used indicators of apoptosis, as measured by flow cytometry and 
Western blotting respectively, were employed to determine the mode of cell death 
induced by HLDA and the ethyl acetate fraction. Both HLDA and the ethyl acetate 
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fraction, from which HLDA was derived, have similar properties in inducing apoptosis 
in the melanoma cells. However, the results from flow cytometry showed that HLDA 
did not modulate cell cycle of the cancer cells but the ethyl acetate fraction did, 
suggesting that the growth inhibitory effect of the ethyl acetate fraction was not solely 
attributed to HLDA but also the other constituents found in the fraction. 
Apoptosis is characterized as a well-ordered, programmed sequence of events for 
cell death, in which loss of mitochondrial membrane potential through the action of the 
Bcl-2 family of proteins, caspase activation, and DNA fragmentation are the hallmarks 
(Gilmore et al., 2000). There are two better-characterized pathways of apoptosis, the 
intrinsic and the extrinsic apoptotic pathways. The upstream initiator caspases, 
caspase-8 and caspase-9 in the extrinsic and intrinsic pathways respectively, converge 
to the downstream effector caspases (Weng et al., 2005). The effector caspases then 
cleave their substrates, such as PARP, so that the cellular, morphological and 
biochemical alterations of apoptosis are ultimately resulted (Cohen, 1997). In addition 
to the elevation of apoptotic peak in the DNA histograms of HLDA- and the 
fraction-treated melanoma cells, PARP cleavage was also observed in the Western blot 
study. The latter observation not only further consolidates the finding that HLDA and 
the fraction induced apoptosis in the melanoma cells, it also indicates that caspases 
might also have been activated to cleave and then inactivate PARP. 
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Both HLDA and the ethyl acetate fraction from S. heptaphylla were shown in this 
study to retard growth of the human melanoma A375 cells by inducing apoptosis. To 
further understand the molecular mechanisms of HLDA- and the ethyl acetate fraction-
induced apoptosis, two important classes of apoptosis-related proteins, i.e. the Bcl-2 
family proteins and caspases were investigated. Results from Western blot analysis 
showed that the HLDA- and the ethyl acetate fraction-induced apoptosis was associated 
with depletion of antiapoptotic Bcl-2 family proteins, including Bcl-2 and BC1-XL. AS 
the ratio of antiapoptotic to proapoptotic Bcl-2 family proteins is critical to the cellular 
decision to live or die (Herzig and Christofori, 2002), disturbance of such ratio by 
HLDA and the fraction in A3 75 cells could explain for their capability to induce 
apoptosis. Previous studies have shown that downregulation of Bcl-2 and BC1-XL may 
promote the oligomerization of Bax subfamily proteins, thereby enhancing the release 
of apoptogenic molecules，such as cytochrome c, from mitochondria and thus initiates 
the degradative cascades of apoptosis (Borner, 2003). 
The roles of caspases in the HLDA- and the ethyl acetate fraction-induced 
apoptosis were studied by using different caspase inhibitors. The results indicated that 
apoptosis induced by HLDA was solely dependent on caspases, while the 
fraction-induced apoptosis was executed by both caspase-dependent and 
caspase-independent events. Apparently, the ethyl acetate fraction contains other 
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phytochemical(s) that could elicit caspase- independent apoptosis. 
Apoptosis can be executed by two main pathways, namely the intrinsic and the 
extrinsic pathways (Earnshaw et al, 1999). Results from Western blot analysis showed 
that both of these pathways were activated upon treatment with either HLDA or the 
ethyl acetate fraction, as indicated by cleavage and thus activation of caspase-8 and 
caspase-9, which are the hallmark and initiator caspases of the intrinsic and extrinsic 
pathways, respectively. Preincubation with either caspase-8 or caspase-9 inhibitor could 
retard the HLDA-induced apoptosis by half in extent. However, the inhibitor retarded 
the cell death process less prominently in the ethyl acetate fraction-induced apoptosis. 
This suggests that the apoptosis might be mediated by some caspase-independent 
events or other initiator caspases, such as caspase-2 and caspase-10. 
Bid, a BH3 domain-only protein, which directly induces Bax and Bak 
oligomerization at the outer mitochondrial membrane, is localized in the cytosolic 
fraction of cells as an inactive precursor (Grinberg et al,, 2002). Cytosolic Bid can be 
cleaved by caspase-8 or caspase 10 in the Fas signaling pathway (Li et al, 1998). Its 
active form, truncated Bid (tBid), translocates to the mitochondria, induces cytochrome 
c release, and activates the mitochondrial death pathway (Letai et al., 2002) Thus, there 
is cross-talk mechanism between the extrinsic and the intrinsic apoptotic pathways 
(Muhlethaler-Mottet et al, 2004). 
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Interestingly, although both the intrinsic and the extrinsic pathways were activated 
by HLDA and the ethyl acetate fraction, the presence of an intact Bid protein suggested 
that the two pathways might be activated independently of one another. However, 
recent studies suggest that direct degradation of Mcl-l by TRAIL-activated caspase-8 
produces Mcl-l-free Bim that mediates a Bax-dependent apoptotic cascade (Weng et 
al., 2005; Han et al, 2006). Thus, we cannot rule out the possibility of the presence of 
unknown candidates that are involved in the cross-talk mechanism between the 
extrinsic and the intrinsic apoptotic pathways in our system. 
By comparing the apoptotic pathways induced by HLDA and the ethyl acetate 
fraction, it is suggested that the apoptotic effect of the fraction was partially mediated 
by HLDA, particularly in the initiation of caspase-dependent events and depletion of 
BCI-XL protein. The caspase-independent events, and the depletion of Bcl-2 protein, on 
the other hand, were attributed to other constituents present in the ethyl acetate fraction. 
In this study, the ethyl acetate fraction from S, heptaphylla was found active in 
retarding growth of human melanoma A375 cells, primarily through induction of 
apoptosis. However, cell-based models cannot accurately model the complex process 
within animals. Thus, two mouse models, including the DMBA/TPA-induced skin 
carcinogenesis and the human xenograft model, were chosen to investigate the cancer 
preventive and therapeutic effects of the fraction in vivo, respectively. 
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The DMBA/TPA-induced skin carcinogenesis model has been widely used to 
determine the chemopreventive effects of different interventions. For example, the 
well-known phytochemicals with cancer preventive activities, such as polyphenols 
from red wine (Soleas et al., 2002)，and curcumin from Curcuma longa (Limtrakul et 
al., 1997) had been studied extensively with the DMBA/TPA model. 
Initiation induced by a single exposure to the initiator, DMBA, causes mutation in 
some critical genes (e.g. c-Ha-ras gene, a gene involved in epidermal proliferation) in 
only a few epidermal cells (Yuspa, 1986; Henning et al., 1993). During the promotion 
stage, repeated application of the promoter, TPA, triggers the epidermal cells to 
undergo selective clonal expansion due to the acquisition of proliferative advantage, 
and the ability to evade apoptotic signals (Muto et al, 2006). 
The DMBA/TPA-induced skin carcinogenesis model was used in this study to 
investigate the cancer preventive properties of the ethyl acetate fraction in vivo. 
Significant inhibition of papilloma development was observed in the fraction-treated 
mice. Moreover, topical application of the fraction at the promotion stage did not cause 
any lethality, suggesting that the fraction is an effective and safe agent against skin 
papilloma development by inhibiting TPA-induced promotion. 
Betulinic acid, a pentacyclic lupane-type triterpene, is structurally similar to 
HLDA derived from the ethyl acetate fraction. It is active in vivo against 
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DMBA/TPA-induced papilloma (Yasukawa et al., 1991). Surprisingly, dose of the 
ethyl acetate fraction as low as 4 mg/ml (i.e. 0.8 mg ethyl acetate fraction dissolved in 
200 \x\ acetone was applied to a 25 g mouse in each treatment), was shown to inhibit the 
papilloma development significantly in the DMBA/TPA model, which is more potent 
than that of betulinic acid (effective dose as 5 |imol, i.e. 2.28 mg in each treatment) 
(Yasukawa et al” 1991). 
Human tumor xenografts implanted subcutaneously (s.c.) into immunosuppressed 
mice have played a significant role in preclinical anticancer drug development in the 
past few years (Bae et al., 2005). Melanoma A375 cells, which were most responsive to 
the ethyl acetate fraction in the in vitro studies, were implanted into nude mice for 
studying the cancer therapeutic effect of the ethyl acetate fraction in vivo. We observed 
that the A3 75 xenografts were significantly reduced in the fraction-treated groups when 
compared to the control group, in term of tumor weight. 
As reported by Pisha et al. (1995), betulinic acid exhibited no toxic effect in mice 
implanted with human xenograft at a concentration of 500 mg/kg, while a dose of 5 
mg/kg was shown to regress xenograft size significantly. In this study, the ethyl acetate 
fraction regressed the size of A375 xenograft significantly at a dose of 2 mg/ml (i.e. 16 
mg/kg) but no toxic effect at 320 mg/kg. Apparently, the data showed that the ethyl 
acetate fraction served better as a chemopreventive agent than a chemotherapeutic 
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agent since 40 mg/ml of the fraction could completely inhibit the papilloma incidence 
in the multistage skin carcinogenesis model whereas the weight of A375 xenografts in 
athymic mice model were only retarded by 84%. The reasons for these observed 
discrepancies between the two models might be due to the differences in their 
principles and duration of treatment. In general, an experimental drug is considered to 
be active when the percentage of growth inhibition of mouse tumor is at least 58% 
(Mattern et al., 1988). Thus, results from in vivo studies strongly evidenced that the 
ethyl acetate fraction is an active anticancer agent. 
This is the first report showing that the components from S. heptaphylla possesses 
strong inhibitory activities against melanoma growth in vivo and in vitro. This suggests 
potential therapeutic roles of the ethyl acetate fraction as an adjuvant for the treatment 
of melanoma (Bae et al., 2005). However, an in-depth study to define the active agent(s) 
in the ethyl acetate fraction capable of affording the observed antitumor-promoting 
effect is highly warranted. 
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